Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | USP1 | O94782 | 1/20 | 0.30 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.30 |
| ▸ | PLG | P00747 | 1/20 | 0.30 |
| ▸ | PLAT | P00750 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700965 | 0.88 | NCF1 (0.39) | NCF1 | |
| SCHEMBL1700960 | 0.88 | NCF1 (0.39) | NCF1 | |
| SCHEMBL25348255 | 0.83 | SLC18A3 (0.31) | NCF1 | |
| SCHEMBL17508766 | 0.81 | NCF1 (0.54) | NCF1CXCR4PLGPLATLMNA | |
| SCHEMBL6379437 | 0.81 | NCF1 (0.45) | NCF1CXCR4 | |
| SCHEMBL15045128 | 0.79 | NCF1 (0.52) | NCF1CXCR4PLGPLATLMNA | |
| SCHEMBL12424517 | 0.78 | USP1 (0.33) | USP1WDR48 | |
| SCHEMBL24818350 | 0.78 | LTA4H (0.33) | USP1WDR48 | |
| SCHEMBL5868081 | 0.77 | NCF1 (0.50) | NCF1 | |
| SCHEMBL23788363 | 0.75 | USP1 (0.32) | USP1WDR48 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4129999-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | The Regents Of The University Of Michigan (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| WO-2022150381-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2022-07-14 | — | — | WO | disclosed |
| EP-3494115-B1 | N-(PHENYLSULFONYL)BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2020-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | NCF1 591/4885CXCR4 2616/4885USP1 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.